$ETNB
89bio, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019046322 Filed on December 18, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q4 2018 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.520M $720.0K $500.0K
YoY Change 204.0%
% of Gross Profit
Research & Development $6.680M $3.690M $3.289M
YoY Change 103.1%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $8.198M $4.410M $3.786M
YoY Change 116.53%
Operating Profit -$8.198M -$4.408M -$3.786M
YoY Change 116.53%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$10.47M -$200.0K -$379.0K
YoY Change 2662.53%
Pretax Income -$18.67M -$4.610M -$4.165M
YoY Change 348.21%
Income Tax $57.00K $30.00K $0.00
% Of Pretax Income
Net Earnings -$18.73M -$4.638M -$4.165M
YoY Change 349.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.553M -$384.7K -$345.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.20M
YoY Change
Cash & Equivalents $16.23M $11.23M $5.528M
Short-Term Investments
Other Short-Term Assets $400.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $16.59M $11.32M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K $33.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.700M
YoY Change
Total Long-Term Assets $1.766M $53.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $16.59M $11.32M
Total Long-Term Assets $1.766M $53.00K
Total Assets $18.35M $11.37M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.571M $1.509M
YoY Change
Accrued Expenses $2.992M $1.173M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.58M $4.353M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $22.58M $4.353M
Total Long-Term Liabilities $0.00
Total Liabilities $22.60M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$54.31M -$16.18M
YoY Change
Common Stock $342.0K $119.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$53.97M -$16.06M -$11.53M
YoY Change
Total Liabilities & Shareholders Equity $18.35M $11.37M
YoY Change

Cashflow Statement

Concept 2019 Q3 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$18.73M -$4.638M -$4.165M
YoY Change 349.58%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change
Cash From Operating Activities -$6.200M -$3.290M -$2.540M
YoY Change 144.09%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$10.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00 -$10.00K
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 490.0K 9.000M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -6.200M -3.290M -2.540M
Cash From Investing Activities -10.00K 0.000 -10.00K
Cash From Financing Activities 490.0K 9.000M 0.000
Net Change In Cash -5.720M 5.710M -2.550M
YoY Change 124.31%
FREE CASH FLOW
Cash From Operating Activities -$6.200M -$3.290M -$2.540M
Capital Expenditures -$10.00K $0.00 -$10.00K
Free Cash Flow -$6.190M -$3.290M -$2.530M
YoY Change 144.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Depreciation
Depreciation
4000
us-gaap Share Based Compensation
ShareBasedCompensation
223000
etnb Deferred Tax Assets
DeferredTaxAssets
69000
etnb Revaluation Of Convertible Preferred Stock Liability
RevaluationOfConvertiblePreferredStockLiability
21018000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
611226
CY2019Q3 us-gaap Deferred Costs
DeferredCosts
1628000
CY2019Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
89000
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
20000
CY2019Q3 etnb Convertible Preferred Stock Liability
ConvertiblePreferredStockLiability
16016000
CY2018Q4 etnb Convertible Preferred Stock Liability
ConvertiblePreferredStockLiability
1671000
CY2018Q4 etnb Ordinary Shares
OrdinaryShares
1000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3289000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
497000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
3786000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-379000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4165000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-62.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-29.79
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
611226
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4887000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-20907000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
74000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14525000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-35358000
CY2019Q3 etnb Effects Of Reorganization Adjustments Value
EffectsOfReorganizationAdjustmentsValue
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
0
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
0
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
0
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
0
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7373000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-7362000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-11527000
us-gaap Profit Loss
ProfitLoss
-38137000
us-gaap Profit Loss
ProfitLoss
-11538000
us-gaap Depreciation
Depreciation
12000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
362000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
16588000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16176000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-16057000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11369000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
611226
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
387334
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54313000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22579000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-53971000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18354000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
118000
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
341000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2019Q3 us-gaap Assets
Assets
18354000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3571000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2992000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4353000
us-gaap Operating Expenses
OperatingExpenses
10754000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10470000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3786000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17029000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.81
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.63
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
112000
us-gaap Net Income Loss
NetIncomeLoss
-38137000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6680000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8198000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8198000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18668000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18725000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1518000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4165000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9989000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2875000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
765000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14154000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10754000
us-gaap Operating Expenses
OperatingExpenses
17029000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21022000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-784000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38051000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11538000
us-gaap Net Income Loss
NetIncomeLoss
-11538000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8329251
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2412739
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
223000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
14665000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
20000000
etnb Revaluation Of Convertible Preferred Stock Liability
RevaluationOfConvertiblePreferredStockLiability
755000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
314000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1610000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1352000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1329000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
302000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14328000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9178000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
100000
etnb Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
686000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19325000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14765000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4969000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5552000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16226000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5552000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5528000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
38000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
24000
etnb Conversion Of Convertible Note Into Preferred Stock
ConversionOfConvertibleNoteIntoPreferredStock
100000
etnb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
942000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, the convertible preferred stock liability and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7245
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0164
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0260
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6180
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-28
etnb Reorganization Exchange Of Equity Percentage Of Common Stock Issued Upon Exchange
ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange
1.00
etnb Reorganization Exchange Of Equity Percentage Of Ordinary Shares Exchanged
ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged
1.00
CY2018Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2019Q3 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
807000
CY2018Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
890000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2185000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
283000
CY2019Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
60000000
CY2019Q3 etnb Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
44000000
CY2019Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
49746000
CY2019Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
44000000
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
60000000
CY2018Q4 etnb Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
24000000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
23073000
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
24000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
72882353
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
611226
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
611226
CY2019Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8538257
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4924545
CY2019Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
4200
CY2018Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
23000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On October 24, 2019, 89bio, Inc.’s board of directors approved the Reverse Split, which was effected on October 25, 2019

Files In Submission

Name View Source Status
0001564590-19-046322-index-headers.html Edgar Link pending
0001564590-19-046322-index.html Edgar Link pending
0001564590-19-046322.txt Edgar Link pending
0001564590-19-046322-xbrl.zip Edgar Link pending
etnb-10q_20190930.htm Edgar Link pending
etnb-20190930.xml Edgar Link completed
etnb-20190930.xsd Edgar Link pending
etnb-20190930_cal.xml Edgar Link unprocessable
etnb-20190930_def.xml Edgar Link unprocessable
etnb-20190930_lab.xml Edgar Link unprocessable
etnb-20190930_pre.xml Edgar Link unprocessable
etnb-ex311_8.htm Edgar Link pending
etnb-ex312_9.htm Edgar Link pending
etnb-ex32_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending